Exploration on pharmacological mechanisms of YZP against neuropathic pain via inhibiting spinal inflammation and the rationality of its compatibility.

导出 LinkOut

翻译打印收藏纠错

第一作者： Dan,Wu

第一单位： Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China.

作者： Dan,Wu ^[1] ; Jin,Su ^[1] ; Ping,Wang ^[1] ; Baorong,Zhai ^[1] ; Chunhui,Zhao ^[1] ; Weijie,Li ^[1] ; Chengyu,Chen ^[2] ; Jianli,Guan ^[3] ; Zhiming,Cao ^[2] ; Naining,Song ^[4] ; Hongjun,Yang ^[5] ; Yanqiong,Zhang ^[6] ; Haiyu,Xu ^[7]

作者单位： Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China. ^[1] Jiaheng (Hengqin, Zhuhai) Pharmaceutical Technology Co. Ltd., Zhuhai, 519000, China. ^[2] Henan Fusen Pharmaceutical Co., Ltd., Nanyang, 474450, China. ^[3] Chinese Academy of Inspection and Quarantine, Beijing, 100176, China. ^[4] Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China. Electronic address: hongjun0420@vip.sina.com. ^[5] Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China. Electronic address: yqzhang@icmm.ac.cn. ^[6] Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China; Key Laboratory for Research and Evaluation of TCM, National Medical Products Administration, China Academy of Chinese Medical Sciences, Beijing, 100700, China. Electronic address: hyxu@icmm.ac.cn. ^[7]

关键词 Compatibility Inflammatory response Neuropathic pain RNA-Seq Yuanhu zhitong prescription